World's Best Scientists 2026 revealed!
Award Badge
Molecular Biology
USA
2026

D-Index & Metrics

Immunology

D-Index
136
Citations
68094
World Ranking
187
National Ranking
121

Medicine

D-Index
136
Citations
68332
World Ranking
1979
National Ranking
1121

Molecular Biology

D-Index
132
Citations
65288
World Ranking
173
National Ranking
108

Malcolm K. Brenner publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Malcolm K. Brenner sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 727 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

Malcolm K. Brenner D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Malcolm K. Brenner sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 132 D-Index — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Molecular Biology in United States Leader Award
  • 2016 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Malcolm K. Brenner is affiliated with the Baylor College of Medicine in the United States. Their research primarily spans the fields of medicine, biochemistry, genetics and molecular biology, as well as immunology and microbiology. Within these areas, their work focuses notably on oncology, immunology, genetics, molecular biology, and hematology.

The scientist has contributed extensively to several core topics including CAR-T cell therapy research, virus-based gene therapy research, immune cell function and interaction, viral infectious diseases and gene expression in insects, T-cell and B-cell immunology, immunotherapy and immune responses, and silicon carbide semiconductor technologies.

Malcolm K. Brenner's frequent co-authors include Helen E. Heslop, Bambi Grilley, Maksim Mamonkin, Huimin Zhang, and Premal Lulla. Their collaboration with these researchers appears across multiple publications, reflecting a sustained research network.

Their publications have appeared in key academic venues such as Blood, Journal of Clinical Oncology, Molecular Therapy, Transplantation and Cellular Therapy, and Journal for ImmunoTherapy of Cancer.

Selected recent papers include:

  • Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma, 2020, Journal of Clinical Oncology
  • Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma, 2020, Nature Communications
  • Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors, 2020, Molecular Therapy
  • Engineered off-the-shelf therapeutic T cells resist host immune rejection, 2020, Nature Biotechnology
  • Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers, 2024, Nature

This scientist's work focuses heavily on therapeutic approaches involving CAR T cells and immunotherapy strategies against various cancers and cellular immune challenges.

Awards recognizing their contributions include membership in the National Academy of Medicine since 2016 and membership in the Association of American Physicians.

Best Publications

  • Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta

    Edwin M. Horwitz;Darwin J. Prockop;Lorraine A. Fitzpatrick;Winston W. K. Koo

  • A distinct "side population" of cells with high drug efflux capacity in human tumor cells.

    C. Hirschmann-Jax;Aaron E. Foster;G. G. Wulf;G. G. Wulf;J. G. Nuchtern

  • Inducible apoptosis as a safety switch for adoptive cell therapy

    Antonio Di Stasi;Siok Keen Tey;Gianpietro Dotti;Yuriko Fujita

  • Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

    Martin A. Pule;Barbara Savoldo;G. Doug Myers;G. Doug Myers;Claudia Rossig

  • Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

    C.M Rooney;C.Y.C Ng;S Loftin;C.A Smith

  • Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

    Chrystal U. Louis;Chrystal U. Louis;Barbara Savoldo;Barbara Savoldo;Gianpietro Dotti;Gianpietro Dotti;Martin Pule

  • Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

    Cliona M. Rooney;Colton A. Smith;Colton A. Smith;Catherine Y.C. Ng;Catherine Y.C. Ng;Susan K. Loftin;Susan K. Loftin

  • CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

    Barbara Savoldo;Carlos Almeida Ramos;Carlos Almeida Ramos;Enli Liu;Martha P. Mims

  • Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

    M.K Brenner;D.R Rill;R.A Krance;J.N Ihle

  • Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

    Nabil Ahmed;Vita S. Brawley;Meenakshi Hegde;Catherine Robertson

  • Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

    Helen E. Heslop;Catherine Y.C. Ng;Congfen Li;Colton A. Smith

  • Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

    Helen E. Heslop;Karen S. Slobod;Martin A. Pule;Gregory A. Hale

  • An inducible caspase 9 safety switch for T-cell therapy

    Karin C. Straathof;Martin A. Pulè;Patricia Yotnda;Gianpietro Dotti

  • HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

    Nabil Ahmed;Nabil Ahmed;Vita Brawley;Vita Brawley;Meenakshi Hegde;Meenakshi Hegde;Kevin Bielamowicz

  • Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta

    Edwin M. Horwitz;Darwin J. Prockop;Patricia L. Gordon;Winston W. K. Koo

  • Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

    Meenakshi Hegde;Malini Mukherjee;Malini Mukherjee;Zakaria Grada;Antonella Pignata

  • Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

    Ann M. Leen;G. Doug Myers;Uluhan Sili;M. Helen Huls

  • Design and development of therapies using chimeric antigen receptor-expressing T cells

    Gianpietro Dotti;Stephen Gottschalk;Barbara Savoldo;Malcolm K. Brenner

  • Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

    Valentina Hoyos;Barbara Savoldo;Barbara Savoldo;Concetta Quintarelli;Aruna Mahendravada

  • Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

    Ann M. Leen;Catherine M. Bollard;Adam M. Mendizabal;Elizabeth J. Shpall

Frequent Co-Authors

Helen E. Heslop
Helen E. Heslop Baylor College of Medicine
Cliona M. Rooney
Cliona M. Rooney Baylor College of Medicine
Gianpietro Dotti
Gianpietro Dotti University of North Carolina at Chapel Hill
Adrian P. Gee
Adrian P. Gee Baylor College of Medicine
Catherine M. Bollard
Catherine M. Bollard George Washington University
Ann M. Leen
Ann M. Leen Baylor College of Medicine
Stephen Gottschalk
Stephen Gottschalk St. Jude Children's Research Hospital
Barbara Savoldo
Barbara Savoldo University of North Carolina at Chapel Hill
Hao Liu
Hao Liu Indiana University
A. V. Hoffbrand
A. V. Hoffbrand The Royal Free Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare degrees can expand career opportunities. Nursing offers diverse pathways, including programs like the easiest np programs to get into, which provide accessible entry points for advancing clinical expertise.

Specializing further, psychiatric nursing is a growing field with impactful roles. You can explore the best pmhnp programs for quality education combined with strong clinical placement support, enhancing real-world experience.

Affordability is always a key consideration. The affordable pmhnp programs offer budget-friendly options without sacrificing educational value, making advanced nursing accessible to more students.

When planning your career, understanding financial outcomes is vital. The dnp salary by specialty data helps inform decisions by outlining earning potentials across states and specialties, guiding you toward rewarding immunology-related roles.

Best Scientists Citing Malcolm K. Brenner

Trending Scientists

Recently Published Articles